Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several negative factors: a significant decline in revenue, reduced gross margins, increased losses, and a major customer's transition impacting sales. Despite management's confidence in margin recovery and ongoing product development, the financial performance remains weak. The Q&A section showed uncertainty regarding future growth and a lack of clarity on strategic impacts, such as the CMS CRUSH initiative. While share repurchases and cash reserves are positive, they don't offset the broader negative sentiment. Given these factors, a negative stock price movement is likely in the short term.
Key Financial Performance
Total Revenue $71.1 million, a decrease of 3.2% year-over-year and 14.6% quarter-over-quarter, driven by the reduction in sales to a large customer transitioning testing in-house.
Precision Diagnostics Revenue $40.2 million, a decrease of 8.8% year-over-year and down 16.5% sequentially, attributed to reduced sales volume.
Anatomic Pathology Revenue $25.1 million, a decrease of 0.9% year-over-year and down 7.2% sequentially, with no specific reasons mentioned.
Biopharma Services Revenue $5.8 million, an increase of 43.2% year-over-year but down 28.0% sequentially, with no specific reasons mentioned.
GAAP Gross Margin 30.2%, reflecting fixed costs over a lower revenue base attributed to the decline in revenue.
Non-GAAP Gross Margin 32.3%, reflecting fixed costs over a lower revenue base attributed to the decline in revenue.
GAAP Operating Expenses $56.1 million, a decrease from $68.8 million in the prior quarter due to a one-time professional liability expense in the prior quarter.
Non-GAAP Operating Expenses $42.6 million, relatively flat compared to $43.1 million in the previous quarter.
GAAP Loss $24.8 million, an increase from the prior quarter's GAAP loss of $23.4 million, attributed to decreased revenue.
Adjusted EBITDA Loss of approximately $15.2 million compared to a loss of $4.5 million in the prior quarter, attributed to decreased revenue.
Non-GAAP Loss Approximately $11 million or $0.36 per share, excluding equity-based compensation expense, intangible asset amortization, acquisition-related costs, and severance.
Cash Position $604.7 million, a decrease of $100.8 million from the previous quarter, primarily driven by $56.6 million paid for acquisitions and $40.1 million spent on stock repurchase program.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EasioPath platform: Achieved approximately 100% visual coverage across all cases, leveraging AI and digital pathology solutions for growth and operational leverage.
FID-007: Advanced through Phase II with 46 patients enrolled; Phase III trial selected for ASCO presentation; demonstrated meaningful anticancer activities and favorable tolerability for head and neck sarcoma cell carcinoma.
FID-022: Progressing through Phase I dose escalation; targeting solid tumors including colon, pancreatic, ovarian, and bile duct cancers.
Whole genome test: Integrated Illumina's TruPath Genome for comprehensive genomic insights, targeting rare disease diagnostics with a single report covering 20,000 genes.
Dermatopathology AI tool: Launched auto-rotation solution for digital slides to improve diagnostic accuracy, workflow efficiency, and reduce turnaround time.
PGx test: Received MolDX approval and pricing; aligns with ASCO's updated guidance for DPYD genotyping in oncology care.
Acquisition of Bako Diagnostics and StrataDx: Expanded market presence in Anatomic Pathology; doubled pathology sales team; focus on cross-training for market expansion.
Pharmacogenomics market: ASCO's updated guidance on DPYD genotyping signals a shift towards routine testing, creating a substantial addressable market in oncology care.
Revenue performance: Q1 revenue at $71.1 million, a decrease due to reduced sales from a major customer transitioning testing in-house.
Stock repurchase program: Repurchased 2.6 million shares in Q1, with $91 million remaining for future repurchases.
Operational investments: Prioritized R&D and sales/marketing expansion, including laboratory infrastructure upgrades and therapeutic development.
Therapeutic development: Focused on advancing clinical trials for FID-007 and FID-022, with significant progress in Phase II and Phase I respectively.
AI and digital pathology: Investments in AI tools like EasioPath and dermatopathology solutions to enhance diagnostic capabilities and operational efficiency.
Customer diversification: Reduced reliance on a single customer, with no customer expected to account for more than 10% of total revenue in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: The company experienced a significant decrease in revenue, particularly from its largest customer, which transitioned testing in-house. This resulted in a $6 million revenue drop from the prior quarter and is expected to continue impacting revenue in the second quarter.
Customer Concentration Risk: The company has historically relied heavily on a single customer for a significant portion of its revenue. Although efforts are being made to diversify, the loss of this customer has already caused a substantial revenue decline.
Integration Challenges: The recent acquisition of Bako Diagnostics and StrataDx requires successful integration, including cross-training sales teams. Any delays or inefficiencies in this process could hinder the anticipated benefits of the acquisition.
Gross Margin Pressure: Gross margins have declined due to fixed costs over a lower revenue base. While improvements are expected, the current margin pressure could impact profitability in the short term.
Regulatory and Operational Delays: The company has faced delays in receiving a $106 million federal income tax refund due to government shutdowns and IRS resource constraints, impacting cash flow.
R&D and Clinical Trial Risks: Significant investments in R&D and clinical trials for FID-007 and FID-022 are ongoing. Any delays, failures, or increased costs in these trials could adversely affect the company's financial position and strategic objectives.
Stock Repurchase Impact: The stock repurchase program has reduced the company's cash reserves by $49 million year-to-date, which could limit financial flexibility for other strategic initiatives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Therapeutic Development Pipeline: The company anticipates an end of Phase II meeting with the FDA for FID-007 in the second half of 2026 and aims to enter a Phase III registration trial for recurrent or metastatic head and neck sarcoma cell carcinoma patients in the first half of 2027. FID-022 is progressing through Phase I dose escalation, with the fourth dose escalation ongoing, and the study is expected to determine the maximum tolerance dose level later this year.
Revenue Guidance for 2026: The company reiterates its topline revenue guidance of $350 million for 2026, representing an 8.5% year-over-year growth. Revenue from Bako Diagnostics and StrataDx is expected to contribute approximately $53 million, primarily in the second half of the year.
Gross Margin and Operating Margin: Non-GAAP gross margins for the full year are expected to be approximately 39%, improving to 42% by the end of the year. Non-GAAP operating margin is projected to be minus 20% for the year.
Capital Expenditures and Cash Position: Capital expenditures for 2026 are projected at $12 million. The company anticipates ending the year with approximately $636 million in cash, cash equivalents, restricted cash, and investments in marketable securities, assuming receipt of a $106 million tax refund.
Stock Repurchase Program: The company has repurchased shares under its stock repurchase program, reducing the forecasted average fully diluted share count for 2026 to approximately 29 million shares. This has resulted in a decrease in non-GAAP EPS guidance by $0.14 to a loss of $1.59 per share.
Customer Revenue Impact: Revenue from the largest customer is expected to stabilize in the second half of the year after a significant decrease in volume in the first half. No single customer is expected to account for more than 10% of total revenue for the full year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: In the first quarter, the company repurchased 2.6 million shares under its stock repurchase program. An additional 0.5 million shares were repurchased in the current quarter, totaling approximately $6.6 million in shares repurchased since the program's inception in March 2022. Approximately $91 million remains available for future repurchases under the program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the underlying business growth for the remainder of the Precision Diagnostics portfolio, excluding the largest customer impact?
A:The underlying Precision Diagnostics business shows growth consistent with Lu Li's calculation, even after excluding the significant impact from the largest customer.
Q:Why was the gross margin in Q1 lower than the initial target of 37%, and how confident is management about reaching 40% in the second half?
A:The lower gross margins were due to lower-than-anticipated revenues caused by reduced volumes from the largest customer, claims processing delays, weather-related lab shutdowns, and seasonality. Management is confident about normalizing gross margins and achieving the 40% target in the second half, supported by revenue uplift and operational improvements.
Q:Was there any impact from acquisitions on the gross margin?
A:No, there was no impact from acquisitions on the gross margin.
Q:What is the company's view on the CMS CRUSH initiative's potential impacts?
A:The company has no comment on the CMS CRUSH initiative's potential impacts at this time.
Q:What was the contribution from StrataDx and Bako in Q1, and what should Q2 look like?
A:The contribution from Bako in Q1 was $2.6 million. Q2 is expected to be higher than Q1 due to the full quarter contribution from Bako and StrataDx, with revenue targets exceeding $90 million per quarter for Q2, Q3, and Q4.
Q:What are the key growth areas in Precision Diagnostics, and how is the company addressing the loss of a large customer?
A:The company is leveraging its diverse portfolio of 22,000 genetic tests, with significant momentum in rare disease diagnostics, whole exome and genome sequencing, rapid genome testing, and pharmacogenetic testing. Beacon and oncology segments are also performing well, helping to offset the loss of the large customer.
Q:What is the outlook for the biopharma business, and is the book-to-bill ratio growing?
A:The biopharma business shows overall momentum but remains lumpy due to large transactions with long sales cycles. Growth is expected in the second half of the year, but peaks and valleys will persist until a steady state is achieved.
Q:What should be expected from the FID-007 Phase II trial presentation at ASCO, and what are the plans for commercialization?
A:The FID-007 Phase II trial results will be presented at ASCO, highlighting its strong clinical performance compared to industry peers. The company is open to partnerships for commercialization but is prepared to continue trials independently if necessary, aiming for collaborations that strengthen its position.
Q:Review of Unclear Management Responses
A:The company avoided giving a direct answer regarding the potential impacts of the CMS CRUSH initiative, stating that they have no comment at this time.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anatomic Pathology
Bako Diagnostics
DPYD testing
Diagnostics StrataDx
Fulgent
III registration
Phase II
Phase III
TruPath Genome
accuracy
acquisition Bako
decrease
dermatopathology
dose
efficacy
error
fluoropyrimidines
item
meeting
notice
opportunity
orientation
positioning
pretreatment
process
read
recurrent head
reduction
repeat expansion
shift integration
slide
toxicity
treatment recurrent
variant repeat
workflow
FLGT Transcript
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call reveals several negative factors: a significant decline in revenue, reduced gross margins, increased losses, and a major customer's transition impacting sales. Despite management's confidence in margin recovery and ongoing product development, the financial performance remains weak. The Q&A section showed uncertainty regarding future growth and a lack of clarity on strategic impacts, such as the CMS CRUSH initiative. While share repurchases and cash reserves are positive, they don't offset the broader negative sentiment. Given these factors, a negative stock price movement is likely in the short term.
Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call presents a mixed picture: strong revenue growth in several segments and improved margins are positive, but significant customer loss and increased expenses are concerning. The optimistic guidance and strategic initiatives in AI and genomics are promising, yet the conservative revenue loss estimate and expected cash burn are potential negatives. The Q&A reveals management's confidence in future growth but lacks clarity on cost synergies and AI strategy. Given these factors, the stock price reaction is likely to be neutral over the next two weeks.
Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call indicates strong financial performance with improved gross margins, reduced operating expenses, and a positive adjusted EBITDA. Revenue guidance has been raised, and there is optimism about future growth due to new product launches and market expansion. While management avoided specific guidance on some aspects, the overall sentiment is positive due to strategic advancements and financial health improvements. The Q&A session provided reassurance on collection issues and highlighted growth drivers, supporting a positive outlook for stock price movement.
FLGT Slides
FLGT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
